Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine for blood pressure and cognitive function in hypertension and cognitive disorder
IRCT20250520065820N1Phase 3Completed
- Sponsor
- Lorestan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of arginine in hypertension (HTN) and cognitive disorder (CD), sponsored by Lorestan University of Medical Sciences. Primary endpoints: Blood pressure change and Cognitive function change. Started Jan 2026; status: completed.
02
Drugs
arginine
03
Conditions
hypertension (HTN)cognitive disorder (CD)
Beyond the preview
Go deeper on IRCT20250520065820N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250520065820N1.